EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility Guidelines
EurekAlert! is a service of the American Association for the Advancement of Science.
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
University of Cincinnati researchers have found that certain treatments for cancer may increase the chance of death if they contract COVID-19.
